Cardiol Therapeutics (CRDL) TD Cowen 45th Annual Healthcare Conference summary

Strategic focus and clinical pipeline

• Advancing therapies targeting inflammation in heart disease, with late-stage development of CardiolRx for recurrent pericarditis and myocarditis.

• Collaborations with leading cardiovascular centers, including Mayo and Cleveland Clinics, to support research and trial execution.

• CRD38, a novel subcutaneous asset for heart failure, is progressing toward IND-enabling studies.

• Lead asset is a synthetic cannabidiol formulation with demonstrated cardioprotective properties.

• Recent publication in the Journal of the American College of Cardiology highlights foundational research.

Clinical trial progress and data highlights

• Phase II Maverick trial in recurrent pericarditis showed rapid and sustained pain reduction, high patient retention, and significant reduction in recurrence rates.

• Phase III Maverick trial aims to enroll 110 high-risk patients, with primary endpoint of freedom from recurrence at 24 weeks.

• ARCHER trial in acute myocarditis completed enrollment of 109 patients across 34 global centers; top-line data expected early Q2.

• CRD38 preclinical data show prevention of cardiac remodeling and reduction in harmful fat distribution.

• Major milestones include completing pericarditis enrollment by first half of 2026 and advancing sub-Q formulation to first-in-man studies.

Market opportunity and forward-looking statements

• Recurrent pericarditis market estimated at $500 million, projected to double in 2–3 years.

• CardiolRx positioned as a non-immunosuppressive, oral, potentially disease-modifying therapy.

• Myocarditis program could inform heart failure development and support label expansion.

• CRD38 targets the large heart failure market, with potential for once-weekly or monthly dosing.

• Ongoing collaborations with global KOLs and anticipation of key inflection points in the next 6–12 months.